RS130-180
| Clinical data | |
|---|---|
| Other names | RS-130-180; N-(2-Propargyloxy)-2,5-dimethoxy-4-(dimethylamino)phenethylamine |
| Drug class | β-Arrestin-biased serotonin 5-HT2A receptor agonist |
| Identifiers | |
| |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C22H28N2O3 |
| Molar mass | 368.477 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RS130-180, also known as N-(2-propargyloxy)-2,5-dimethoxy-4-(dimethylamino)phenethylamine, is a β-arrestin-biased serotonin 5-HT2A receptor agonist of the phenethylamine, 2C, and NBOMe families. It is the NBOMe derivative in which the phenyl ring has an N,N-dimethylamino substitution at the 4 position and the 2-position methoxy group on the benzyl ring has been replaced with a propynyloxy group.
The drug favors activation of β-arrestin signaling over Gq signaling. RS130-180 is said to be useful for in-vitro studies, but to have suboptimal pharmacokinetic properties for in-vivo use. β-Arrestin-biased serotonin 5-HT2A receptor agonists do not produce the head-twitch response in rodents and it is thought that they may be non-hallucinogenic in humans. The cryo-EM structures of the serotonin 5-HT2A receptor with RS130-180, as well as with various serotonergic psychedelics, have been solved and published by Bryan Roth and colleagues.
RS130-180 was first described in the literature by 2022. It was derived from an earlier compound called ZINC000341335936, which was identified via in-silico screening of 1.6 billion molecules for serotonin 5-HT2A receptor agonism with AlphaFold2. RS130-180 was developed via structural modification of ZINC000341335936 by David E. Nichols and colleagues.